Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Investigating the makeup of malignant rhabdoid tumours
RNA‐sequencing to characterise malignant rhabdoid tumour heterogeneity: a pilot study in archival frozen material
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Improving our understanding of brain tumours in teenagers and young adults
Teenagers and young adults with primary CNS cancers: a systematic biological characterisation
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Developing a blood test to monitor ependymoma treatment and follow-up
Minimal residual disease detection of ependymoma by microRNA biomarker profile evaluation as part of SIOP Ependymoma II trial
Do national advisory panels improve outcomes for patients?
Evaluation of national advisory panels for childhood cancer